A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy

NCT05798026 | Recruiting Phase 1

• 1 other identifier: EU-CTS103-I-01
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 3

Brief Summary

Phase 1 (dose escalation) of this study will evaluate: The safety and tolerability of EU103 treatment are evaluated for patients with advanced or metastatic solid tumors who have failed standard therapy to determine the maximum tolerated dose and recommended Phase 2 dose. And preliminary efficacy (tumor response), The pharmacokinetic characteristics are evaluated, and changes are investigated.

Conditions

Solid Tumor

Outcome Measures

Primary Outcomes (7)

• Adverse Event (AEs) and Serious Adverse Events (SAEs) and Adverse Events

  Number of Participants With Adverse Event (AEs) and Serious Adverse Events (SAEs) and Adverse Events Leading to Discontinuation

  Baseline up to 30 months

• Dose Limiting Toxicity (DLT)

  Number of Participants With Dose Limiting Toxicity (DLT)

  At the end of Cycle 1 (Each cycle is of 21 Days)

• Phase 1:Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

  Laboratory assessments include hematology, serum chemistry, other blood tests, coagulation, and urine analysis. Number of participants with clinically significant abnormalities will be reported.

  Time Frame: Baseline up to 24 months

• Number of participants with clinically significant abnormalities

  Vital signs will include body temperature, pulse rate, and systolic and diastolic blood pressure measurements. Number of participants with clinically significant abnormalities will be reported.

  Time Frame: Baseline up to 24 months

• Phase 1:Number of Participants With Clinically Significant Abnormalities in Physical Examination

  Physical examination will include head, eyes, ears, nose and throat; heart; lungs; abdomen; skin; cervical and axillary lymph nodes; and neurological and musculoskeletal systems. Number of participants with clinically significant abnormalities will be reported.

  Time Frame: Baseline up to 24 months

• Phase 1:Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG)Physical Examination

  ECG parameters included heart rhythm, pulse rate intervals, QRS, QT intervals, RR intervals and corrected QT(QTc) intervals. Number of participants with clinically significant abnormalities will be reported.

  Time Frame: Baseline up to 24 months

• Phase 1:Production of anti-drug antibodies (ADAs)

  The number of subjects, percentage, and Exact 95% confidence interval for subjects who are anti-drug antibody (ADA) positive at each measurement time point compared to before administration of investigational drugs are presented for each dose level.

  Time Frame: Baseline up to 30 months

Secondary Outcomes (7)

• Phase 1:Objective response rate (ORR)

  Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 24 months)

• Phase 1:Duration of response (DoR)

  Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 24 months)

• Phase 1:Disease control rate (DCR)

  Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 24 months)

• Phase 1:Time to response (TTR)

  Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 24 months)

• Phase 1:Time to progression (TTP)

  Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 24 months)

Study Arms (7)

EU103: Dose Escalation Cohort

EXPERIMENTAL

Participants with advanced solid tumors will receive EU103 intravenously once every 3 weeks (3 weeks = 1 cycle) with escalating doses starting from 1 milligrams per kilogram (mg/kg) for each cohort and increasing to 3, 6, 12 or 24 mg/kg until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.

Drug: EU103

EU103: Dose Escalation Cohort 1

EXPERIMENTAL

1 mg/kg

Drug: EU103

EU103: Dose Escalation Cohort 2

EXPERIMENTAL

3 mg/kg

Drug: EU103

EU103: Dose Escalation Cohort 3

EXPERIMENTAL

6 mg/kg

Drug: EU103

EU103: Dose Escalation Cohort 4

EXPERIMENTAL

12 mg/kg

Drug: EU103

EU103: Dose Escalation Cohort 5

EXPERIMENTAL

24 mg/kg

Drug: EU103

Backfill cohort

OTHER

Additional subjects can be registered at doses confirmed to be safety

Drug: EU103

Interventions

EU103 DRUG

EU103 will be administered via intravenous infusion.

Backfill cohort; EU103: Dose Escalation Cohort; EU103: Dose Escalation Cohort 1; EU103: Dose Escalation Cohort 2; EU103: Dose Escalation Cohort 3; EU103: Dose Escalation Cohort 4; EU103: Dose Escalation Cohort 5

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult males or females aged 18 years (or 19 years according to local regulatory requirements) or older at the time of obtaining written consent
• Patients with histologically or cytologically confirmed unresectable advanced or metastatic solid tumors who have failed locally known standard therapies or are unable to apply any more standard therapies.
• Patients with at least 1 measurable or non-measurable lesion per RECIST v1.1
• Patients with an estimated survival of 3 months or longer, as determined by the investigator
• Patients with ECOG PS 0-2
• Patients with adequate bone marrow, liver, and renal functions at the time of screening
• Absolute Neutrophil Count (ANC) ≥ 1,500 /μL
• Platelet ≥ 100,000 /μL
• Hemoglobin ≥ 9.0 g/dL (If the hemoglobin level of a patient is below 9.0 g/dL, he/she may be enrolled upon recovery to 9.0 g/dL or higher. However, blood transfusions performed in order to meet this criterion within 14 days before screening are not allowed.)
• AST and/or ALT ≤ 2.5x ULN (≤ 5 x ULN if liver metastases are present)
• Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if liver metastases are present)
• Serum creatinine ≤1.5 x ULN
• \* However, if serum creatinine is \>1.5 x ULN, Creatinine clearance (CrCl) ≥ 60 mL/min is allowed for enrollment.
• PT (INR) ≤1.5 x ULN
• Those who provide or can provide newly obtained tumor biopsies (preferred) or archived tumor tissue specimens during the screening period.

You may not qualify if:

• Patients who have received prior anticancer therapy, monoclonal antibodies, chemotherapy, live vaccines, or other investigational products, or have a history of treatment with an investigational medical device within 4 weeks prior to the first dose of the investigational product
• Patients who have not recovered (to Grade 1 or better, or the baseline level per NCI-CTCAE v5.0) from the adverse events (excluding alopecia) caused by prior anticancer therapy based on the start date of the first dose of the investigational product
• Patients with a history of radiotherapy within 2 weeks prior to the investigational product administration Note. Subjects must have recovered from all radiation-related toxicities, not require corticosteroid use, and have no history of radiation pneumonitis. A 1-week recovery period is allowed for palliative radiotherapy (not more than 2 weeks of radiotherapy) for diseases other than the central nervous system (CNS) diseases.
• Patients with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, idiopathic pneumonia, or evidence of active pneumonia, or past history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or evidence of clinically active ILD
• Patients with symptomatic ascites or pleural effusion Note. Enrollment is allowed if clinically stable after treatment for the condition (including thoracentesis or paracentesis for therapeutic purposes).
• Patients with uncontrolled tumor-related pain (Patients with symptomatic lesions that can be treated with palliative radiotherapy \[e.g., bone metastases or metastases causing nerve impingement\] can be enrolled after treatment prior to screening).
• Patients with known symptomatic, untreated, or actively progressing brain metastases and/or leptomeningeal disease
• Patients who have had or currently have any of the following infections:
• Individuals with a history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) (However, patients with human immunodeficiency virus (HIV) who have no history of opportunistic infection and a CD4+ T cell (CD4+) count ≥350 cells/uL within 12 months prior to screening are allowed for enrollment)
• Patients with active hepatitis B (However, those who have negative HBV titer based on the determination of the study site within 14 days prior to screening, have received antiviral therapy for at least 14 days prior to screening and are willing to maintain it throughout the study period are eligible for enrollment.)
• Patients with active hepatitis C (However, if patients have completed antiviral treatment and their HCV viral load is negative based on the determination of the study site, they are eligible for enrollment.)
• Patients with active infection accompanied by uncontrolled severe chronic infection or requiring treatment
• Patients who have been diagnosed with a malignancy other than the indication in this study within 5 years prior to screening (However, patients who have been assessed as having complete response after treatment and have not relapsed within at least 3 years from the time of screening, or patients with non-melanoma skin cancer, in-situ disease, thyroid cancer, or borderline tumors are eligible for enrollment)
• Patients with severe cardiac diseases clinically significant as determined by the investigator
• \* Including but not limited to the following diseases: uncontrolled hypertension, congestive heart failure \[NYHA Grade 2 or higher\], ventricular arrhythmia, active ischemic heart disease, myocardial infarction within 1 year prior to screening, QTcF ≥ 450 ms (males) / ≥ 470 ms (females), or other cardiac diseases that, in the judgment of the investigator, preclude participation in this study.

Sponsors & Collaborators

• Eutilex: lead

Study Sites (3)

Asan Medical Center

Seoul, South Korea

RECRUITING

Samsung Seoul Hospital

Seoul, South Korea

RECRUITING

Seoul National University Hospital

Seoul, South Korea

RECRUITING

Central Study Contacts

DongMin Shin

CONTACT

82-2-2071-3318; dmshin@eutilex.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 22, 2023
• First Posted: April 4, 2023
• Study Start: August 8, 2023
• Primary Completion: April 30, 2025
• Study Completion: December 31, 2025
• Last Updated: March 13, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will not share

Locations

KR (3)